- Advanced search
- Immuno Portal
- Malaria Portal
|International Nonproprietary Names|
|MABp1 | RA-18C3 | Xilonix® (proposed trade name)|
|Bermekimab (MABp1, Xilonix) is an investigational fully human monoclonal antibody targeting IL-1α, with potential antiinflammatory action. This antibody is the first genuinely human monoclonal antibody to be produced directly from an affinity matured, human immune response. As MABp1 has not been subject to in vitro sequence modification it is predicted to have improved tolerability compared to antibodies that are 'humanised'.
A patent search suggests that Xilonix is the subject of WO2009148575 .
|GtoPdb PubChem SID||249565769|
|Search PubMed clinical trials||bermekimab|
|Search PubMed titles||bermekimab|
|Search PubMed titles/abstracts||bermekimab|